Sio Gene Therapies to Participate in Upcoming Conferences

Rhea-AI Summary

Sio Gene Therapies Inc. (NASDAQ: SIOX) announced participation in multiple upcoming investor and scientific conferences in April 2021, focusing on gene therapies for neurodegenerative diseases. Key events include Guggenheim's Healthcare Talks on April 1, featuring a panel on CNS indications, and the Alliance for Regenerative Medicine conference on April 6, discussing commercialization in advanced therapies. Additionally, Sio will present on GM1 and GM2 gangliosidosis during NTSAD’s conference on April 23. These efforts reflect Sio's commitment to advancing gene therapies for conditions like Tay-Sachs and Parkinson's disease.

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences in April. Details can be found below.

Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Day

Participation:	Panel discussion and 1-on-1 investor meetings
Panel Title:	Emerging Approaches Targeting CNS Indications Like FTD and GM1
Panel Presenter:	Pavan Cheruvu, MD, Chief Executive Officer
Panel Date & Time:	Thursday, April 1, 2021 at 12:00 PM ET
Webcast:	https://kvgo.com/guggenheim/sio-gene-therapies-april-2021

Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean

Participation:	Panel discussion and corporate presentation
Panel Title:	Innovation: Shortening the Path to Commercialization in Advanced Therapies
Panel Presenter:	Parag V. Meswani, PharmD, Chief Commercial Officer
Date:	April 6, 2021
The company presentation and panel discussion will be available to view on-demand throughout the entirety of the conference. Please visit www.meetingonthemed.com for full information including registration.

NTSAD’s 43^rd Annual Family Conference

Participation:	Presentations on GM1 and GM2 gangliosidosis (Tay-Sachs/Sandhoff disease) programs
Date & Time:	April 23, 2021 from 2:00-4:00 PM ET
Both sessions will occur concurrently and are available to all attendees who can register for the event here.

The company will also participate in a number of medical events throughout April including the ACMG Annual Clinical Genetics Meeting, AAN 2021 Virtual Annual Meeting, and the Virtual World Orphan Drug Congress USA 2021.

About Sio Gene Therapies

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.

Contacts:

Media

Josephine Belluardo, Ph.D.
LifeSci Communications
(646) 751-4361
jo@lifescicomms.com
info@siogtx.com

Investors and Analysts

Parag V. Meswani
Sio Gene Therapies Inc.
Chief Commercial Officer
investors@siogtx.com

FAQ

What conferences will Sio Gene Therapies participate in during April 2021?

Sio Gene Therapies will participate in Guggenheim's Healthcare Talks on April 1, the Alliance for Regenerative Medicine conference on April 6, and NTSAD’s Annual Family Conference on April 23.

What is the purpose of Sio Gene Therapies' participation in these conferences?

The purpose is to discuss advancements in gene therapies for neurodegenerative diseases and to engage with investors and stakeholders.

Who will represent Sio Gene Therapies at the Guggenheim Healthcare Talks?

Pavan Cheruvu, MD, the Chief Executive Officer, will represent Sio Gene Therapies at the Guggenheim Healthcare Talks.

What topics will be covered in Sio's presentations at the NTSAD conference?

Sio will present on GM1 and GM2 gangliosidosis programs, which include Tay-Sachs and Sandhoff diseases.

How can I view Sio Gene Therapies' presentations from the conferences?

Presentations will be available on-demand at the respective conference websites, including www.meetingonthemed.com.